OCULAR THERAPEUTIX INC's ticker is OCUL and the CUSIP is 67576A100. A total of 141 filers reported holding OCULAR THERAPEUTIX INC in Q4 2021. The put-call ratio across all filers is 1.20 and the average weighting 0.8%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $102,395 | -33.9% | 32,610 | +8.7% | 0.00% | – |
Q2 2023 | $154,826 | -17.1% | 30,005 | -15.3% | 0.00% | – |
Q1 2023 | $186,663 | +119.6% | 35,420 | +16.5% | 0.00% | – |
Q4 2022 | $85,000 | -50.6% | 30,400 | -26.7% | 0.00% | – |
Q3 2022 | $172,000 | +4.9% | 41,458 | +1.5% | 0.00% | – |
Q2 2022 | $164,000 | +76.3% | 40,858 | +116.5% | 0.00% | – |
Q1 2022 | $93,000 | -40.0% | 18,868 | -15.1% | 0.00% | – |
Q4 2021 | $155,000 | -4.3% | 22,218 | +94.7% | 0.00% | – |
Q2 2021 | $162,000 | -12.9% | 11,413 | +1.1% | 0.00% | – |
Q1 2021 | $186,000 | -29.5% | 11,290 | -11.4% | 0.00% | – |
Q4 2020 | $264,000 | +137.8% | 12,740 | -12.6% | 0.00% | – |
Q3 2020 | $111,000 | -5.1% | 14,570 | +3.6% | 0.00% | – |
Q2 2020 | $117,000 | +20.6% | 14,070 | -28.2% | 0.00% | – |
Q1 2020 | $97,000 | +125.6% | 19,588 | +78.0% | 0.00% | – |
Q4 2019 | $43,000 | +30.3% | 11,005 | +0.0% | 0.00% | – |
Q3 2019 | $33,000 | – | 11,000 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
SUMMER ROAD LLC | 6,122,089 | $32,263 | 100.00% |
Opaleye Management Inc. | 6,105,900 | $32,178,093 | 9.64% |
DELTEC ASSET MANAGEMENT LLC | 1,913,612 | $10,084,735 | 2.49% |
Knoll Capital Management, LLC | 200,000 | $1,504,000 | 2.32% |
Endurant Capital Management LP | 512,744 | $2,702,161 | 1.39% |
Knoll Capital Management, LLC | 95,800 | $504,866 | 0.78% |
Covestor Ltd | 60,008 | $316 | 0.28% |
Ikarian Capital, LLC | 200,000 | $1,054,000 | 0.24% |
EAM Investors, LLC | 224,211 | $1,181,592 | 0.23% |
Nebula Research & Development LLC | 22,474 | $118,438 | 0.21% |